ADTRAN
Adtran today announced that together with BT Group it has conducted Europe’s first successful field trial of optical transport in a live research network, using Adtran’s Coherent 100ZR pluggable transceiver. Achieving high levels of spectral efficiency and low power consumption, the trial demonstrated the transceiver’s ability to enable the transport of 100Gbit/s wavelengths, over longer distances, across routes at metro and edge aggregation networks, offering scalable and efficient solutions for the future.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240322463892/en/
Adtran’s Coherent 100ZR pluggable transceiver can be used to quickly scale networks without major infrastructure changes. (Photo: Business Wire)
With demand for speed and bandwidth growing, there is a need to increase the transport capacity of access and edge aggregation networks. As such, operators need cost-efficient solutions that can be easily deployed to upgrade certain routes without making major changes to existing infrastructure.
About the size of a memory stick, the Adtran Coherent 100ZR transceiver can be plugged directly into an operator‘s transmission unit. Featuring a purpose-built digital signal processor (DSP) co-developed with Coherent Corp that is optimized for data rates of 100Gbit/s and designed for easy integration with deployed infrastructure, the QSFP28-compatible transceiver facilitates the adoption of 100ZR coherent technology at the network edge.
“Adtran’s plug-and-play solution has enabled us to demonstrate the feasibility of boosting capabilities within existing networks and doing so in a cost-effective and scalable manner,” said Andrew Lord, senior manager of optics research at BT. “As we continue to innovate and push boundaries, technologies like this will be instrumental in achieving our goals for a greener, more efficient telecommunications landscape.”
The trial with BT Group was conducted across a complex network infrastructure, spanning 90km over a third-party optical line system, incorporating four ROADM nodes and six amplifiers. Utilizing a tight 50GHz ROADM channel, the trial achieved enhanced spectral efficiency. Operating at less than 5 watts, the trial also set new benchmarks for energy efficiency.
“Together with BT Group, we’ve showcased a method for transforming network infrastructure with highly efficient, low-power solutions. It’s a strategy that requires significantly less equipment and fewer sites. The demo also proves the advantages of deploying one amplifier in the optical line system rather than multiple amplifiers within each transceiver module. This streamlined approach helps boost network performance, reduces operational spending and shrinks carbon footprint. As well as big potential savings – as much as 50% in some cases – this strategy offers a clear path to more sustainable network development,” commented Ryan Schmidt, GM of optical transport at Adtran. “This demo also highlights the exceptional performance of our outdoor-hardened Coherent 100ZR transceiver. Despite its relatively low optical launch power, it excelled within a complex, real-life ROADM network.”
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
Published by
ADTRAN Holdings, Inc.
www.adtran.com
About BT Group
BT Group is the UK’s leading provider of fixed and mobile telecommunications and related secure digital products, solutions and services. We also provide managed telecommunications, security and network & IT infrastructure services to customers across 180 countries.
BT Group consists of three customer-facing units: Consumer serves individuals and families in the UK; Business covers companies and public services in the UK and internationally; Openreach is an independently governed, wholly owned subsidiary wholesaling fixed access infrastructure services to its customers - over 650 communications providers across the UK.
British Telecommunications plc is a wholly owned subsidiary of BT Group plc and encompasses virtually all businesses and assets of the BT Group. BT Group plc is listed on the London Stock Exchange.
For more information, visit www.bt.com/about.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240322463892/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Shield and PwC UK Forge Strategic Collaboration to Deliver Future-Ready Communications Compliance18.9.2025 08:00:00 CEST | Press release
Collaboration brings together Shield's AI-first platform with PwC's surveillance expertise to deliver measurable compliance outcomes Shield, a leading AI platform for digital communication governance and archiving, today announced a collaboration with PwC UK, one of the world’s most trusted professional services firms. The alliance brings together Shield’s unified, cloud-native solution with PwC’s specialist expertise in communications surveillance delivery, regulatory compliance and complex programme execution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917394739/en/ Shield and PwC launch a strategic collaboration to modernize eComms surveillance with AI-driven compliance solutions for financial institutions. The collaboration is designed to support institutions as they modernise their approach to communications monitoring, helping them implement an advanced and proactive risk management approach at scale and with co
Almirall Presents Long‑Term Results from First Real‑World Dermatology Study Using WHO‑5 Well‑Being Index as Primary Endpoint in the treatment of Psoriasis at EADV 202518.9.2025 08:00:00 CEST | Press release
Results of the POSITIVE study assessing the treatment with tildrakizumab showed sustained improvements in skin clearance, psychological well-being, and improved partner quality of life in adults with moderate-to-severe psoriasis over two years.POSITIVE is the first real-world evidence (RWE) study in dermatology to use the WHO-5 Well-Being Index as a primary endpoint, complementing traditional measures of skin disease (PASI, PGA), quality of life (DLQI), with the assessment of psychological well-being, marking a paradigm shift towards holistic management of psoriasis.The POSITIVE study highlights Almirall’s leadership in advancing patient-centred dermatology aligned with the WHO’s health definition and recent resolution on skin diseases.Almirall’s extensive scientific contributions to EADV 2025 include 44 abstracts across key dermatological conditions including atopic dermatitis, psoriasis, actinic keratosis, and hidradenitis suppurativa, and two expert-led symposia. Almirall, S.A. (ALM
Curatis: FDA Minutes Confirm Positive Outcome of Meeting on 9. September 2025 – Corticorelin on Track for Phase 318.9.2025 07:00:00 CEST | Press release
Curatis Holding AG (SIX:CURN) received the official minutes from the FDA meeting which took place on 9. September. Based on the totality of the feedback and discussions, Curatis can proceed as planned with the clinical development of corticorelin. Corticorelin is under development as a novel treatment intended to reduce or even eliminate steroid use and associated toxicities thereby potentially impacting the quality of life of patients suffering from peritumoral brain edema (PTBE) associated with metastatic (secondary) brain tumors. The virtual meeting with the FDA provided the opportunity to discuss the clinical development plan for corticorelin and encompassed CMC (Chemistry, Manufacturing and Control), nonclinical and clinical aspects. The offical FDA minutes which Curatis received after publication of the half year results reflect the positive outcome. Curatis may proceed without delay to a regulatory submission supporting a pivotal study in patients suffering from PTBE secondary t
Galderma Launches Transformative Skincare Segment With Cetaphil’s New Skin Activator Hydrating & Firming Line, in Partnership With Actor and Filmmaker Mariska Hargitay18.9.2025 07:00:00 CEST | Press release
Cetaphil's new Skin Activator Hydrating & Firming Line harnesses a proprietary formula, co-created with dermatologists and offering targeted, high-performance skincare designed to improve the appearance of skin affected by dermatoporosis The line’s new Skin Activator technology uses microdosed alpha hydroxy acid (AHA) and encapsulated centella asiatica (CICA) to wake up sleeping surface skin cells To help bring this segment-defining product line to life, Cetaphil is partnering with acclaimed actress, director, and advocate, Mariska Hargitay, a powerful voice in embracing beauty at every stage Galderma today announced Cetaphil, the dermatologist-recommended brand trusted by millions with sensitive skin, is redefining daily skincare with its new Skin Activator Hydrating & Firming line. The launch marks an entirely new skincare segment of advanced hydration and firming solutions designed specifically for improving the appearance of aging, thinning, and fragile skin. As people age, surface
Merck Opens Climate-Neutral €150 Million Filter Manufacturing Facility in Ireland18.9.2025 07:00:00 CEST | Press release
Part of company’s €440 million investment in Ireland, strengthens Merck’s in-region-for-region supply resilienceMerck’s first climate-neutral manufacturing facility, powered by 100 percent renewable electricityNew Blarney site in Cork, Ireland expands filter manufacturing capacity, creating more than 200 jobs by 2028 Merck, a leading science and technology company, has opened today its €150 million filter manufacturing facility in Blarney Business Park, Cork, Ireland. The site is Merck’s first manufacturing facility designed for full climate-neutral operations, marking a key milestone in the company’s ambition to achieve climate neutrality by 2040. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917767425/en/ Merck's new Blarney site in Cork expands company's filter capacity, creating 200+ jobs by 2028 The 3,000-square-meter cleanroom facility supports global demand for critical filtration products used in the manufacturin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom